CClinicalTrials.gg
RecruitingNCT07324031ALARION EVUpdated Sep 3, 2026

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

An interventional study of Atala™ lead and EV-ICD Pulse Generator in Ventricular Arrythmia, Ventricular Fibrillation and Ventricular Tachycardia, sponsored by AtaCor Medical, Inc.. Recruiting at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AtaCor Medical, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.

The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.

Read the detailed description

The primary safety endpoint is Freedom from Major Adverse Device Effects (MADEs) through 6 months. The primary effectiveness endpoint is Defibrillation Performance: Successful induced ventricular arrhythmia (IVA) test in the final system configuration.

Up to 40 Investigational Sites Worldwide will participate with up to 280 subjects enrolled in the study. At least 50% of subjects will be enrolled at sites in the United States.

Subjects meeting indications for ICD therapy who do not require permanent bradycardia pacing will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to an EV-ICD Pulse Generator positioned in a left pectoral or left lateral location. The Parasternal EV-ICD System will be tested to verify appropriate sensing and defibrillation.

Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to be ongoing for a minimum of 2.5 years from the date of first enrollment. Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 6-month visit.

02

Conditions studied

  • Ventricular Arrythmia
  • Ventricular Fibrillation
  • Ventricular Tachycardia

Keywords

  • Ventricular Defibrillation
  • Extravascular
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. At least 18 years old
  2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Exclusion criteria

Exclusion Criteria:

  1. Patients who cannot read or write
  2. Expected survival \< 1 year
  3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  4. Participation in any concurrent clinical study without prior approval from the Sponsor
  5. Inability or unwillingness to provide informed consent to participate in the study
  6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit
  7. Circumstances that may prevent data collection or completion of specified follow-up visits
  8. Allergies to any device materials listed in the Instructions for Use (IFU)
  9. Contraindication for temporary suspension of oral/systemic anticoagulation
  10. Known history of lung disease with FEV1 \< 1.0 Liter

    Device Related:

  11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator
  12. Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
  13. Any known need for MRI prior to approval of MRI conditional labeling

    Anatomy Related:

  14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure
  15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead
  16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type
  17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
  18. History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure
  19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
  20. Surgically corrected congenital heart disease (not including catheter-based procedures)

    Cardiac Related:

  21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy
  22. Decompensated heart failure
  23. Currently on inotropic therapy
  24. Known history of pericardial disease, pericarditis or mediastinitis
  25. Risk factors associated with defibrillation testing:

    • Severe aortic stenosis
    • Current Intracardiac LA or LV thrombus
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Hemodynamic instability
    • Unstable angina
    • Recent stroke or transient ischemic attack (within the last 3 months)
    • Known inadequate external defibrillation
    • LVEF \< 20% (most recent assessment; must be within 180 days of consent)
    • LVEDD >70 mm (most recent assessment; must be within 180 days of consent)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Parasternal EV-ICD System

    Subjects implanted with the Atala™ lead and EV-ICD pulse generator

    Device: Atala™ lead and EV-ICD Pulse Generator

Interventions

  • DeviceAtala™ lead and EV-ICD Pulse Generator

    Subjects will receive the Atala™ lead and EV-ICD pulse generator being evaluated in the study.

05

What researchers measure

Primary outcomes

  1. Freedom from MADEs

    Freedom from Major Adverse Device Effects (MADEs)

    Time frame: Through 6 months post-implant

  2. Successful IVA Test

    Successful induced ventricular arrhythmia (IVA) test in the final system configuration

    Time frame: At the time of procedure and up to 60 days post-implant

06

Study locations

11 of 35 sites recruiting
  • Honor Health
    Scottsdale, Arizona 85258, United States
    • Rahul Doshi, MD · Contact
    • Rahul Doshi, MD · Principal investigator
    Not yet recruiting
  • St. Bernards Heart and Vascular
    Jonesboro, Arkansas 72401, United States
    • Devi Nair, MD · Contact
    • Devi Nair, MD · Principal investigator
    Recruiting
  • UC San Diego Health
    La Jolla, California 92037, United States
    • Ulrika Birgersdotter-Green, MD · Contact
    • Ulrika Birgersdotter-Green, MD · Principal investigator
    Not yet recruiting
  • Providence Medical Foundation
    Orange, California 92868, United States
    • Thuy Le, MD · Contact
    • Thuy Le, MD · Principal investigator
    Not yet recruiting
  • Cedars-Sinai Medical Center
    Santa Monica, California 90404, United States
    • Shephal Doshi, MD · Contact
    • Shephal Doshi, MD · Principal investigator
    Not yet recruiting
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    • Cyrus Hadadi, MD · Contact
    • Cyrus Hadadi, MD · Principal investigator
    Not yet recruiting
  • Mount Sinai Medical Center of Florida
    Miami Beach, Florida 33140, United States
    • Raul Weiss, MD · Contact
    • Raul Weiss, MD · Principal investigator
    Not yet recruiting
  • AdventHealth
    Orlando, Florida 32803, United States
    • Naushad Shaik, MD · Contact
    • Naushad Shaik, MD · Principal investigator
    Not yet recruiting
  • Emory University
    Atlanta, Georgia 30308, United States
    • Mikhael El Chami, MD · Contact
    • Mikhael El Chami, MD · Principal investigator
    Recruiting
  • Endeavor Health
    Glenview, Illinois 60026, United States
    • Mark Metzl, MD · Contact
    • Mark Metzl, MD · Principal investigator
    Recruiting
  • Baptist Health
    Lexington, Kentucky 40503, United States
    • Johan Aasbo, DO · Contact
    • Johan Aasbo, DO · Principal investigator
    Recruiting
  • John Hopkins Medical
    Baltimore, Maryland 21287, United States
    • Edward Powers, MD · Contact
    • Edward Powers, MD · Principal investigator
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
    • Paul Friedman, MD · Contact
    • Paul Friedman, MD · Principal investigator
    Recruiting
  • Cooper Health
    Voorhees Township, New Jersey 08043, United States
    • Andrea Russo, MD · Contact
    • Andrea Russo, MD · Principal investigator
    Not yet recruiting
  • Northwell Health
    Manhasset, New York 11030, United States
    • Laurence Epstein, MD · Contact
    • Laurence Epstein, MD · Principal investigator
    Recruiting
  • Advocate/Atrium Health - Sanger Heart and Vascular
    Charlotte, North Carolina 28204, United States
    • Satish Misra, MD · Contact
    • Satish Misra, MD · Principal investigator
    Recruiting
  • East Carolina Heart Institute at ECU
    Greenville, North Carolina 27834, United States
    • Rajesekhar Nekkanti, MD · Contact
    • Rajesekhar Nekkanti, MD · Principal investigator
    Not yet recruiting
  • North Carolina Heart and Vascular
    Raleigh, North Carolina 27607, United States
    • Sidharth Shah, MD · Contact
    • Sidharth Shah, MD · Principal investigator
    Not yet recruiting
  • Novant Health
    Winston-Salem, North Carolina 27103, United States
    • Michael Drucker, MD · Contact
    • Michael Drucker, MD · Principal investigator
    Not yet recruiting
  • Advocate/Atrium Health - Wake Forest Baptist
    Winston-Salem, North Carolina 27157, United States
    • Satish Misra, MD · Contact
    • Satish Misra, MD · Principal investigator
    Recruiting
  • The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital
    Cincinnati, Ohio 45219, United States
    • Daniel Pelchovitz, MD · Contact
    • Daniel Pelchovitz, MD · Principal investigator
    Not yet recruiting
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
    • Judith Mackall, MD · Contact
    • Judith Mackall, MD · Principal investigator
    Not yet recruiting
  • OhioHealth Research Institute
    Columbus, Ohio 43228, United States
    • Anish Amin, MD · Contact
    • Anish Amin, MD · Principal investigator
    Not yet recruiting
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
    • Soraya Samii, MD · Contact
    • Soraya Samii, MD · Principal investigator
    Not yet recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    • Robert Schaller, MD · Contact
    • Robert Schaller, MD · Principal investigator
    Not yet recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    • Anne Kroman, DO · Contact
    • Anne Kroman, DO · Principal investigator
    Not yet recruiting
  • Texas Cardiac Arrhythmia Research
    Austin, Texas 78705, United States
    • Amin Al-Ahmad, MD · Contact
    • Amin Al-Ahmad, MD · Principal investigator
    Recruiting
  • Haga Hospital
    The Hague, AA 2545, Netherlands
    • Shmaila Saleem-Talib, MD · Contact
    • Shmaila Saleem-Talib, MD · Principal investigator
    Not yet recruiting
  • Isala Hospital
    Zwolle, AB 8025, Netherlands
    • Sébastien Krul, MD · Contact
    • Sébastien Krul, MD · Principal investigator
    Not yet recruiting
  • Amsterdam University Medical Center
    Amsterdam, AZ 1105, Netherlands
    • Louise Olde Nordkamp, MD · Contact
    • Louise Olde Nordkamp, MD · Principal investigator
    Recruiting
  • St. Antonius Hospital
    Nieuwegein, CM 3435, Netherlands
    • Vincent Van Dijk, MD · Contact
    • Vincent Van Dijk, MD · Principal investigator
    Not yet recruiting
  • Erasmus Medical Center
    Rotterdam, Gelderland 3015, Netherlands
    • Sing Yap, MD · Contact
    • Sing Yap, MD · Principal investigator
    Not yet recruiting
  • Maastricht University Medical Center
    Maastricht, HX 6229, Netherlands
    • Twan van Stipdonk, MD · Contact
    • Twan van Stipdonk, MD · Principal investigator
    Not yet recruiting
  • Medical Spectrum Twente
    Enschede, KZ 7512, Netherlands
    • Jurren van Opstal, MD · Contact
    • Jurren van Opstal, MD · Principal investigator
    Not yet recruiting
  • University Medical Center Groningen
    Groningen, RB 9700, Netherlands
    • Michiel Rienstra, MD · Contact
    • Michiel Rienstra, MD · Principal investigator
    Not yet recruiting
07

Registry details

Key details

Study ID
NCT07324031
Lead sponsor
AtaCor Medical, Inc.
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jul 2, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Sarah Hase, BS, CCRA
Contact
sarah@atacor.com
+1 949-545-9820

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion